LobbyingPremier lobbying by quarter
Premier's latest lobbying report covers Q2 2026, at $140K. The four quarters Q4 2025–Q3 2026 total $550K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Premier
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $550K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $320K | 2 |
| Q1 2023 | $300K | 2 |
| Q2 2023 | $330K | 2 |
| Q3 2023 | $280K | 2 |
| Q4 2023 | $350K | 2 |
| Q1 2024 | $130K | 1 |
| Q2 2024 | $225K | 1 |
| Q3 2024 | $173K | 1 |
| Q4 2024 | $180K | 1 |
| Q1 2025 | $140K | 1 |
| Q2 2025 | $210K | 1 |
| Q3 2025 | $210K | 1 |
| Q4 2025 | $190K | 1 |
| Q1 2026 | $220K | 1 |
| Q2 2026 | $140K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$3M · 15 reports
- Medicare and Medicaid$350K · 5 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES20 reports
- SENATE20 reports
- Centers For Medicare and Medicaid Services (CMS)13 reports
- Health & Human Services, Dept of (HHS)13 reports
- Executive Office of the President (EOP)8 reports
- Food & Drug Administration (FDA)8 reports
- Health Resources & Services Administration (HRSA)5 reports
- Office of Management & Budget (OMB)5 reports
- White House Office5 reports
- Centers For Disease Control & Prevention (CDC)3 reports
- Drug Enforcement Administration (DEA)3 reports
- Federal Emergency Management Agency (FEMA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-housePremier | $3M | 15 quarters |
| Alston & Bird | $350K | 5 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/18for Q2 | In-house | $140K |
| 04/20for Q1 | In-house | $220K |
| 01/20for Q4 2025 | In-house | $190K |
| 25/10/20for Q3 2025 | In-house | $210K |
| 25/07/21for Q2 2025 | In-house | $210K |
| 25/04/18for Q1 2025 | In-house | $140K |
| 25/01/30for Q1 2025 | In-house | Under $5,000 |
| 25/01/17for Q4 2024 | In-house | $180K |
| 24/10/21for Q3 2024 | In-house | $173K |
| 24/07/19for Q2 2024 | In-house | $225K |
| 24/04/15for Q1 2024 | In-house | $130K |
| 24/01/18for Q4 2023 | In-house | $320K |
| 23/11/17for Q4 2023 | Alston & Bird | $30K |
| 23/10/20for Q3 2023 | Alston & Bird | $80K |
| 23/10/17for Q3 2023 | In-house | $200K |
| 23/07/20for Q2 2023 | Alston & Bird | $80K |
| 23/07/14for Q2 2023 | In-house | $250K |
| 23/04/20for Q1 2023 | Alston & Bird | $80K |
| 23/04/17for Q1 2023 | In-house | $220K |
| 23/01/20for Q4 2022 | Alston & Bird | $80K |